What Mycamine contains
- The active substance is micafungin sodium. 1 vial contains 50 mg or 100 mg micafungin (as sodium).
- The other ingredients are lactose monohydrate, citric acid anhydrous and sodium hydroxide.
What Mycamine looks like and contents of the pack
Mycamine 50 mg or 100 mg powder for solution for infusion is a white compact freeze-dried powder. Mycamine is supplied in a box containing 1 vial.
Marketing Authorisation Holder
Astellas Pharma Europe B.V.
Elisabethhof 19
2353 EW Leiderdorp
Netherlands
Manufacturer
Astellas Ireland Co., Ltd.
Killorglin, County Kerry
Ireland
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
BelgiëBelgiqueBelgien Astellas Pharma B.V. Branch Erasmus ParkParc Erasme Square Marie Curie 50 B-1070 BrüsselBruxelles TélTel 32 02 5580710 . 6 1407 Te. 359 2 862 53 72 LuxembourgLuxemburg Astellas Pharma B.V. Branch Erasmus ParkParc Erasme Square Marie Curie 50 B-1070 BrüsselBruxelles BelgiqueBelgien TélTel 32 02 5580710 Magyarország Astellas Pharma Kft. Kelenhegyi út 43 H-1118 BudapestB.III Tel. 36 061 3614673
eská republika Astellas Pharma s.r.o. Sokolovskà 10094 CZ-18600 Praha 8 Tel 420 236 080300 Malta E.J. Busuttil Ltd. Niche Triq ix-Xorrox MT-Bkara BKP 12 Tel 356 21 447184
Danmark Astellas Pharma as Naverland 4 DK-2600 Glostrup Tlf 45 43430355 Nederland Astellas Pharma B.V. Elisabethhof 19 NL-2353 EW Leiderdorp Tel 31 071 5455745
Deutschland Astellas Pharma GmbH Georg-Brauchle-Ring 64 66 D-80992 München Tel 49 089 454401 Norge Astellas Pharma Solbråveien 47 N-1383 Asker Tlf 47 6676 4600
Eesti Astellas Pharma Europe B.V. Elisabethhof 19 NL-2353 EW Leiderdorp Österreich Astellas Pharma Ges.m.b.H. Linzer Straße 221E02 A-1140 Wien
Tel 43 01 8772668 Holland Tel 31 071 5455745 Astellas Pharmaceuticals AEBE 1 GR-14565, T 30 210 8189900 Polska Astellas Pharma Sp.z o.o. ul. Poleczki 21 PL-02-822 Warszawa Tel. 48 0 225451 111
España Astellas Pharma S.A. Paseo del Club Deportivo n 1 Bloque 14-2a Planta E-28223 Pozuelo de Alarcón, Madrid Tel 34 91 4952700 Portugal Astellas Farma, Lda. Edifício Cinema Rua José Fontana, n.1, 1Andar P-2770-101 Paço de Arcos Tel 351 21 4401320
France Astellas Pharma S.A.S. 114 rue Victor Hugo F-92300 Levallois Perret Tél 33 01 55917500 România S.C.Astellas Pharma SRL Detalii de contact pentru România oseaua Bucureti-Ploieti 42-44 Cldire 1, Parter 013696-Bucureti - RO Tel 40 021 361 04 95
Slovenija Astellas Pharma Europe B.V. Elisabethhof 19 NL-2353 EW Leiderdorp Nizozemska Tel 31 071 5455745 Ireland Astellas Pharma Co. Ltd. 25, The Courtyard Kilcarbery Business Park Nangor Road Clondalkin IRL-Dublin 22 Tel 353 01 4671555
Ísland Vistor hf. Hörgatúni 2 IS-210 Garðabær Tel 354 535 7000 Slovenská republika Astellas Pharma s.r.o., organizaná zloka Galvániho 15C SK-821 04 Bratislava Tel 421 2 4444 2157
Italia Astellas Pharma S.p.A. Via delle Industrie 1 I-20061 Carugate Milano Tel 39 02 921381 SuomiFinland Algol Pharma Oy PL 13 FIN-02611 EspooEsbo PuhTel 358 9 50991
Sverige Astellas Pharma AB Per Albin Hanssons väg 41 S-205 12 Malmö Tel 46 040-650 15 00 Astellas Pharmaceuticals AEBE 1 GR-14565, T 30 210 8189900
Latvija Astellas Pharma Europe B.V. Elisabethhof 19 NL-2353 EW Leiderdorp Nderlande Tel 31 071 5455745 United Kingdom Astellas Pharma Ltd. Lovett House Lovett Road, Staines Middlesex, TW18 3AZ Tel 44 0 1784 419615
Lietuva
Astellas Pharma Europe B.V.
Elisabethhof 19
NL-2353 EW Leiderdorp
Nyderlandai
Tel: +31 (0)71 5455745
This leaflet was last approved in {MM/YYYY}.
---------------------------------------------------------------------------------------------------------------------------
The following information is intended for medical or healthcare professionals only:
Mycamine must not be mixed or co-infused with other medicinal products except those mentioned below. Using aseptic techniques at room temperature, Mycamine is reconstituted and diluted as follows:
1. The plastic cap must be removed from the vial and the stopper disinfected with alcohol.
2. Five ml of sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion (taken from a 100 ml bottle/bag) should be aseptically and slowly injected into each vial along the side of the inner wall. Although the concentrate will foam, every effort should be made to minimise the amount of foam generated. A sufficient number of vials of Mycamine must be reconstituted to obtain the required dose in mg (see table below).
3. The vial should be rotated gently. DO NOT SHAKE. The powder will dissolve completely. The concentrate should be used immediately. The vial is for single use only. Therefore, please discard unused reconstituted concentrate immediately.
4. All of the reconstituted concentrate should be withdrawn from each vial and returned into the infusion bottle/bag from which it was originally taken. The diluted infusion solution should be used immediately. Chemical and physical in-use stability have been demonstrated for 96 hours at 25°C when protected from light and diluted as described above.
5. The infusion bottle/bag should be gently inverted to disperse the diluted solution but NOT agitated in order to avoid foaming. Do not use if the solution is cloudy or has precipitated.
6. The infusion bottle/bag containing the diluted infusion solution should be inserted into a closable opaque bag for protection from light.
Preparation of the solution for infusion
Dose mg Mycamine vial to be used mgvial Volume of sodium chloride 0.9 or glucose 5 to be added per vial Volume concentration of reconstituted powder Standard infusion added up to 100 ml Final concentration 50 1 x 50 5 ml 0.5 mgml approx. 5 ml 10 mgml 100 1 x 100 5 ml 1.0 mgml approx. 5 ml 20 mgml 150 5 ml approx. 10 ml 1.5 mgml 1 x 100 1 x 50 200 2 x 100 5 ml approx. 10 ml 2.0 mgml
ANNEX IV
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below i.e. the details of a prescription checklist are implemented:
- Mycamine is contra-indicated if the patient has a history of hypersensitivity to micafungin or excipients.
- Mycamine should not be used during pregnancy unless clearly necessary.
- Caution must be demonstrated if the patient:
- has severe liver function impairment
- has chronic liver diseases known to represent preneoplastic conditions (e.g. advanced liver fibrosis, cirrhosis, viral hepatitis, neonatal liver disease or congenital enzyme defects)
- is receiving a concomitant therapy including hepatotoxic and/or genotoxic properties
- has history of haemolysis, haemolytic anaemia or renal impairment.
- Patients receiving sirolimus, nifedipine or itraconazole in combination with Mycamine should be monitored for sirolimus, nifedipine or itraconazole toxicity and the sirolimus, nifedipine or itraconazole dosage should be reduced if necessary.
- Patients should be carefully monitored for liver damage and for worsening of renal function.
- To minimise the risk of adaptive regeneration and potentially subsequent liver tumour formation, early discontinuation in the presence of significant and persistent elevation of ALT/AST is recommended.